Rhine Shen
About Rhine Shen
Rhine Shen is a Senior Director of Translational Medicine at Kite Pharma, where he leads teams in developing innovative cancer treatments. He has extensive experience in immunotherapy development and has worked at various prestigious institutions throughout his career.
Current Role at Kite Pharma
Rhine Shen serves as the Senior Director of Translational Medicine at Kite Pharma, a position he has held since 2021. In this role, he leads cross-functional teams focused on the development of innovative cancer treatments. His responsibilities include overseeing translational research initiatives aimed at advancing immunotherapy options for patients.
Previous Experience at Kite Pharma
Prior to his current role, Rhine Shen worked at Kite Pharma as a Principal Scientist from 2019 to 2021. During this time, he contributed to the development of cancer therapies, leveraging his expertise in immunotherapy and drug discovery to support the company's mission in oncology.
Background in Immuno-Oncology
Rhine Shen has extensive experience in the field of immuno-oncology. He has a strong focus on translational research and drug discovery, particularly in developing immunotherapies such as CAR-T, bispecifics, and antibody-drug conjugates (ADC). His work aims to bridge the gap between laboratory research and clinical application.
Education and Expertise
Rhine Shen earned his Ph.D. in Cellular and Molecular Pathology from UCLA. He also holds a Bachelor of Science degree in Biochemistry from The University of Texas at Austin. His educational background provides a solid foundation for his expertise in cancer research and immunotherapy development.
Professional History at Dana-Farber and Atara Biotherapeutics
Before joining Kite Pharma, Rhine Shen held various positions in notable institutions. He was a Postdoctoral Fellow at Dana-Farber Cancer Institute, Harvard Medical School, from 2006 to 2013. He also worked at Atara Biotherapeutics, where he served as Principal Scientist and later as Associate Director of Preclinical and Translational Science in 2019.